Darzalex (daratumumab)

November 5, 2019

Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple ... Read more

September 27, 2019October 16, 2019

Compass Self Storage Raises $100K for the Leukemia & Lymphoma Society’s Children’s Initiative

News

Compass Self Storage has raised more than $100,000 this year for the Leukemia & Lymphoma Society (LLS), particularly for its children’s initiative. The $101,618 raised brings to more than $500,000 ... Read more

April 5, 2017

Janssen Hits Snag with Darzalex Phase 2 Trial for Non-Hodgkin’s Lymphoma

News

Stage 1 of the Phase 2 trial of Darzalex (daratumumab) in relapsed or refractory non-Hodgkin’s lymphomas has failed to reach the predefined thresholds of overall response rates in the follicular lymphoma (FL) ... Read more